5/9/2025

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other Jim Cramer stocks with huge upside potential. During the episode of Mad Money aired on Wednesday, Jim Cramer broke down […]

Source: Yahoo

5/9/2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Source: Yahoo

5/8/2025

Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Source: MarketWatch

5/8/2025

We recently compiled a list of the 11 Cheap ESG Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other cheap ESG stocks. These days, it seems like everyone wants to wear the “saving the world” cape. Whether this […]

Source: Yahoo

5/7/2025

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against Billionaire Mario Gabelli’s other large-cap stock picks with huge upside potential. Mario Gabelli needs no introduction, having risen to become […]

Source: Yahoo

5/6/2025

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

Source: MarketWatch

5/6/2025

On April 18, 2025, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the supplemental Biologics License Application for...

Source: Finnhub

5/6/2025

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at AMGN stock after its Q1 earnings.

Source: SeekingAlpha

5/5/2025

Kiniksa Pharmaceuticals surpasses Q1 expectations, raises ARCALYST sales guidance. Read the latest earnings review here on Seeking Alpha.

Source: SeekingAlpha

5/2/2025

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

5/2/2025

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

Source: Yahoo

5/2/2025

TARRYTOWN - Regeneron Pharmaceuticals, Inc. announced 24 abstracts on Dupixent clinical data and real-world analyses in respiratory diseases will be presented at the American Thoracic Society ...

Source: Finnhub

5/2/2025

TARRYTOWN - Regeneron Pharmaceuticals, Inc. announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology Annual Meeting,...

Source: Finnhub

5/1/2025

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment to highlight the top-performing stocks since […]

Source: Yahoo

5/1/2025

Regeneron Pharmaceuticals (NasdaqGS:REGN) is poised for an eventful month, highlighting exciting advancements in their cancer and respiratory disease treatments at upcoming conferences. Following a week where the broader market witnessed a 2.7% rise, Regeneron’s stock nudged up 1.86%. Although the company’s announcements regarding its oncology and hematology findings, in addition to the European approval for Lynozyfic™, could generate interest, the market’s overall positive momentum, partly...

Source: Yahoo

5/1/2025

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day

Source: MarketWatch

5/1/2025

REFINITIV STREETEVENTS EDITED TRANSCRIPT REGN.OQ - Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call EVENT DATE/TIME: APRIL 29, 2025 / 12:30PM GMT ...

Source: Finnhub

5/1/2025

Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm is reducing its expected Eylea sales given the company’s near-term outlook, though while near-term investor focus remains on the Eylea tail, Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving bre

Source: Yahoo

5/1/2025

18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodiesTARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, IL. Eighteen presentations will share the latest insights

Source: Yahoo

5/1/2025

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation Asthma abstracts include late-breaking data on mucus burden and the first presentation of efficacy results from a Phase

Source: Yahoo